Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

(2015) S.Y. Brulé et al.   EUROPEAN JOURNAL OF CANCER

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

(2015) A. Stahler et al.   INTERNATIONAL JOURNAL OF CANCER

Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

(2015) Fotios Loupakis et al.   JNCI-Journal of the National Cancer Institute

Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

(2015) Fotios Loupakis et al.   JNCI-Journal of the National Cancer Institute

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

(2015) Huili Li et al.   Oncotarget

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

(2014) E. Missiaglia et al.   ANNALS OF ONCOLOGY

Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer

(2014) Xiaojing Yang et al.   CANCER CELL

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

(2014) S. M. Cushman et al.   CLINICAL CANCER RESEARCH

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

(2014) J. C. von Einem et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

(2013) George Pentheroudakis et al.   BMC CANCER

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

(2013) D J Jonker et al.   BRITISH JOURNAL OF CANCER

PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

(2013) Christos S. Karapetis et al.   CLINICAL CANCER RESEARCH

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data

(2012) Wenting Wang et al.   BIOINFORMATICS

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

(2012) Carsten Bokemeyer et al.   EUROPEAN JOURNAL OF CANCER

Colorectal cancer: a tale of two sides or a continuum?: Figure 1

(2012) Mai Yamauchi et al.   GUT

Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers

(2012) Jiyeon Yun et al.   LABORATORY INVESTIGATION

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Functions of DNA methylation: islands, start sites, gene bodies and beyond

(2012) Peter A. Jones   NATURE REVIEWS GENETICS

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

(2011) J B Baker et al.   BRITISH JOURNAL OF CANCER

Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines

(2011) Sabine Hagemann et al.   PLoS One

Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis

(2010) Pan Du et al.   BMC BIOINFORMATICS

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

(2010) Jolien Tol et al.   EUROPEAN JOURNAL OF CANCER

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Conserved role of intragenic DNA methylation in regulating alternative promoters

(2010) Alika K. Maunakea et al.   NATURE

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2009) Bart Jacobs et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE